[1] Yasuda S, Ide M, Fujii H, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer, 2000, 83(12):1607-1611.
[2] Chen YK, Ding HJ, Su CT, et al. Application of PET and PET-CT imaging for cancer screening. Anticancer Res, 2004, 24(6):4103-4108.
[3] Ide M, Suzuki Y. Is whole-body FDG-PET valuable for health screening?. Eur J Nucl Med Mol Imaging, 2005, 32(3):339-341.
[4] Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community:the Pescopugano survey. J Clin Endocrinol Metab, 1999, 84(2):561-566.
[5] Brander AE, Viikinkoski VP, Nickels JI, et al. Importance of thyroid abnormalities detected at US screening:a 5-year follow-up. Radiology, 2000, 215(3):801-806.
[6] Pacini F, Burroni L, Ciuoli C, et al. Management of thyroid nodules:a clinicopathological, evidence-based approach. Eur J Nucl Med Mol Imaging, 2004, 31(10):1443-1449.
[7] Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US:Society of Radiologists in Ultrasound consensus conference statement. Radiology, 2005, 237(3):794-800.
[8] Kang KW, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incident Loma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metaba, 2003, 88(9):4100-4104.
[9] Cohen MS, Arslan N, Dohdashti F, et al. Risk of malignancy in thyroid ineidentalomas identified by flurodeoxyglueose positron emission tomography. Surgery, 2001, 130(6):941-946.
[10] Kim TY, Kim WB, Ryu JS, et al. 18F-FDG uptake in thyroid from PET for evaluation in cancer patients:high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope, 2005, 115(6):1074-1078.
[11] Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med, 2001, 42(7):989-992.
[12] Israel O, Yefremov N, Bar-Shalom R, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake:incidence, localization patterns, and clinical significance. J Nucl Med. 2005, 46(5):758-762.
[13] Kamel EM, Thumshim M, Truninger K, et al. Signigicance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET-CT:correlation with endoscopic and histopathologic results. J Nucl Med, 2004, 45(11):1804-1810.
[14] Silverman D, Screening 18F-FDG whole-body scanning:AWESOMPET or FALSPOS-PET?. J Nucl Med, 2005, 46(5):717.
[15] Schöder H, Yeung HW, Gonen M, et al. Head and neck cancer:clinical usefulness and accuracy of PET-CT image fusion. Radiology, 2004, 231(1):65-72.
[16] Cohade C, Osman M, Leal J, et al. Direct comparison of 18F-FDG PET and PET-CT in patients with colorectal carcinoma. J Nucl Med, 2003, 44(11):1797-1803.
[17] Antoch G, Saoudi N, Kuchl H, et al. Accuracy of whole-body dualmodality 18F-FDG PET and PET-CT for tumor staging in solid tumors:comparison with CT and PET. J Clin Oncol, 2004, 22(21):4357-4368.
[18] Deloar HM, Fujiwara T, Shidahara M, et al. Estimation of absorbed dose for 18F-FDG using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med, 1998, 25(6):565-574.
[19] Brix G. Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET-CT examinations. J Nucl Med, 2005, 46(4):608-613.
[20] International Commission on Radiological Protection.Recommendatio ns of the International Commission on Radiological Protection.Oxford. England:Pergamon Press:1991. Publication 60.
[21] Black WC. Over diagnosis:An under recognized cause of confusion and harm in cancer screening. J Natl Cancer Inst, 2000, 92(16):1280-1282.
[22] Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst, 2002, 94(3):167-173.
[23] Kopans DB, Monsees B, Feig SA. Screening for cancer:when it valid? Lessons from the mammography experience. Radiology, 2003, 229(2):319-327.